as 05-30-2025 4:00pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Founded: | 2001 | Country: | United States |
Employees: | N/A | City: | WESTLAKE VILLAGE |
Market Cap: | 94.0M | IPO Year: | 2023 |
Target Price: | $17.75 | AVG Volume (30 days): | 159.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.88 | EPS Growth: | N/A |
52 Week Low/High: | $1.60 - $5.88 | Next Earning Date: | 05-06-2025 |
Revenue: | N/A | Revenue Growth: | -95.29% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Zindrick Thomas | GNLX | President and CEO | May 12 '25 | Sell | $2.92 | 10,764 | $31,430.88 | 191,447 | |
Ryder Sean | GNLX | General Counsel | May 12 '25 | Sell | $2.92 | 4,475 | $13,067.00 | 47,621 | |
Smalling Ralph | GNLX | Head of Regulatory | May 12 '25 | Sell | $2.92 | 1,259 | $3,676.28 | 34,760 | |
Cappello Joseph | GNLX | VP, Pharmaceutical Development | May 12 '25 | Sell | $2.92 | 4,737 | $13,832.04 | 52,266 |
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Zacks
a month ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
Zacks
2 months ago
MT Newswires
2 months ago
MT Newswires
2 months ago
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.